



Dear Valued Customer,

Resmed is committed to supporting patients who rely on Astral ventilators and helping our customers manage their existing Astral fleets. As part of that commitment, we want to provide you with an important update regarding the future of the Astral portfolio.

Astral product lifecycle update

Ongoing supply constraints affecting critical electronic components have created significant challenges for the continued manufacture of Astral ventilators.

Following a thorough assessment of the long-term component supply outlook,

Resmed has made the decision to obsolete the Astral ventilator portfolio, effective September 14, 2026. This decision enables us to prioritize available components and resources toward existing patients and continuity of care.

Affected products include Astral 100 (27001) and Astral 150 (27003).

What this means for customers and patients

Astral is not available for general commercial purchase. Any remaining finished goods within our distribution channels will be allocated through existing controlled processes to support continuity of care and delivery of the Field Safety Corrective Action (FSCA), subject to local inventory availability.

Resmed plans to continue providing accessories, spare parts, service and maintenance support for Astral through December 31, 2034, subject to applicable regulatory requirements, supply availability, service capacity and local customer obligations. We will make sustained and reasonable efforts to maintain this support throughout the planned service support period.

Patients can continue using their devices in accordance with applicable clinical guidance unless otherwise advised by their treating clinician. Over the coming months, we will continue working alongside you to support your installed base, help you plan for future ventilation requirements and manage the transition.

For customers affected by the Field Safety Corrective Action (FSCA) The FSCA is separate from this product obsolescence decision and remains active and unchanged.

For customers and patients within the scope of the FSCA, this notice does not change existing FSCA instructions, patient guidance or Resmed's corrective action commitments.

Customers not within the scope of the FSCA do not need to take any action related to the FSCA as a result of this notice.

Resmed is prioritizing available components and resources to support existing patients, including activities associated with the FSCA.

Our commitment to Breathing Health

The decision to obsolete Astral is specific to this product and does not change Resmed's long-term commitment to Breathing Health. Breathing Health remains central to Resmed's mission. We remain committed to supporting people living with chronic respiratory conditions through connected, home-based care and continue to invest in home-based non-invasive ventilation (NIV) and related solutions.

Looking ahead

If you have questions about existing contracts, tenders, commercial commitments, or this notice, please contact your local Resmed representative.

Thank you for the trust you have placed in Astral over many years and for your continued partnership in supporting patients who rely on ventilation therapy.

Sincerely,

A handwritten signature in black ink that reads "Sean Redmond". The signature is written in a cursive, flowing style.

Sean Redmond
Director, Breathing Health